New antibody drug targets autoimmune diseases in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called OM336 in 39 adults with active Sjogren's disease or idiopathic inflammatory myopathy who have not improved with at least two prior treatments. OM336 is an engineered antibody designed to target and potentially reduce harmful immune c…
Phase: PHASE1 • Sponsor: Ouro Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC